A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer
A Phase Ib/II Study of PEP503 (Radioenhancer) With Radiotherapy, in Combination With Concurrent Chemotherapy for Patients With Locally Advanced or Unresectable Rectal Cancer
Sponsor: PharmaEngine
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from PharmaEngine
Other Rectal Cancer trials with similar outcome
A PHASE1/PHASE2 clinical study on Rectal Cancer, this trial is terminated or withdrawn. The trial is conducted by PharmaEngine and has accumulated 9 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
-
Apr 2021 — Feb 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 4 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2018 — Feb 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- PharmaEngine
For direct contact, visit the study record on ClinicalTrials.gov .